Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate

2019 ◽  
Vol 26 (6) ◽  
pp. 301-306
Author(s):  
Mohsen Ebrahimi Monfared ◽  
Shima Shapoori ◽  
Ghasem Mosayebi ◽  
Behzad Khansarinejad ◽  
Ali Ghazavi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Interferon Β ◽  
Multiple Sclerosis Patients

scholarly journals Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate

2020 ◽  
Vol 11 ◽  
Author(s):  
Justin M. Honce ◽  
Kavita V. Nair ◽  
Brian D. Hoyt ◽  
Rebecca A. Seale ◽  
Stefan Sillau ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Brain Atrophy ◽  
Multiple Sclerosis Patients

scholarly journals Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients

2016 ◽  
Vol 3 (2) ◽  
pp. e202 ◽  
Author(s):  
Harald Hegen ◽  
Indra Adrianto ◽  
Christopher J. Lessard ◽  
Alban Millonig ◽  
Antonio Bertolotto ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Β ◽  
Cytokine Profiles ◽  
Multiple Sclerosis Patients

scholarly journals Metabolic response to glatiramer acetate therapy in multiple sclerosis patients

BBA Clinical ◽  
2016 ◽  
Vol 6 ◽  
pp. 131-137 ◽  
Author(s):  
Lidia De Riccardis ◽  
Alessandra Ferramosca ◽  
Antonio Danieli ◽  
Giorgio Trianni ◽  
Vincenzo Zara ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Metabolic Response ◽  
Multiple Sclerosis Patients

scholarly journals Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study

2021 ◽  
Vol 7 (4) ◽  
pp. 205521732110615
Author(s):  
Peter Rieckmann ◽  
Robert Zivadinov ◽  
Alexey Boyko ◽  
Krzysztof Selmaj ◽  
Jessica K. Alexander ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Low Frequency ◽  
Exposure Period ◽  
Similar Efficacy ◽  
Open Label ◽  
Open Label Extension ◽  
Multiple Sclerosis Patients ◽  
Relapsing Multiple Sclerosis

Objective Describe the long-term outcomes of early-start (ES) and delayed-start (DS) glatiramer acetate 40 mg/mL treatment three times weekly (GA40) for up to seven years in the Glatiramer Acetate Low-frequency Administration (GALA) study in patients with relapsing multiple sclerosis (RMS). Methods Patients were evaluated every three to six months. The primary efficacy endpoint was annualized relapse rate (ARR); additional endpoints were exploratory or post hoc. For efficacy, data from the entire exposure period were used for the ES and DS cohorts. For safety, exposure only under GA40 was considered. Results Of the patients who continued into the open-label extension (OLE), 580/834 (70%) ES and 261/419 (62%) DS completed the OLE. For the entire placebo-controlled and OLE study period, ARR was 0.26 for ES and 0.31 for DS patients (risk ratio = 0.83; 95% confidence interval [CI]: 0.70–0.99). ES prolonged median time to first relapse versus DS (4.9 versus 4.3 years; hazard ratio = 0.82; 95% CI: 0.6–0.96). OLE-only results showed DS patients experienced similar efficacy for relapse and disability outcomes as ES patients. Adverse events were consistent with the well-established GA safety profile. Conclusions GA40 treatment conferred clinical benefit up to seven years, resulting in sustained efficacy and was generally well tolerated in RMS patients.

Sign in / Sign up

Export Citation Format

Share Document